New York Life Investment Management LLC Sells 398 Shares of United Therapeutics Co. (NASDAQ:UTHR)

New York Life Investment Management LLC lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 7.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,661 shares of the biotechnology company’s stock after selling 398 shares during the quarter. New York Life Investment Management LLC’s holdings in United Therapeutics were worth $1,645,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in UTHR. Geode Capital Management LLC increased its stake in United Therapeutics by 4.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock valued at $391,459,000 after buying an additional 45,566 shares during the last quarter. FMR LLC increased its position in shares of United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after acquiring an additional 314,004 shares during the last quarter. Pacer Advisors Inc. raised its holdings in United Therapeutics by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock worth $210,869,000 after acquiring an additional 30,931 shares in the last quarter. Janus Henderson Group PLC boosted its position in United Therapeutics by 12.3% during the third quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock valued at $164,978,000 after purchasing an additional 50,409 shares during the last quarter. Finally, Assetmark Inc. grew its stake in United Therapeutics by 56.9% in the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after purchasing an additional 152,249 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 1.1 %

Shares of UTHR stock opened at $319.96 on Monday. United Therapeutics Co. has a 12-month low of $221.53 and a 12-month high of $417.82. The company has a market capitalization of $14.28 billion, a PE ratio of 14.05, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. The firm has a 50 day moving average price of $359.65 and a two-hundred day moving average price of $360.97.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. During the same period last year, the firm posted $4.36 EPS. As a group, research analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Activity

In related news, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at $13,743,122.70. This represents a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the transaction, the director now directly owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 124,164 shares of company stock valued at $45,278,893. 11.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on UTHR shares. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday. UBS Group increased their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Thursday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.